Rate My Professor Chris Bacon

Dr Christopher M. Bacon serves as Senior Lecturer and Honorary Consultant in Haematopathology in the Faculty of Medical Sciences at Newcastle University, formerly the University of Newcastle-upon-Tyne. Qualified with MBChB and PhD degrees, he is based in the Translational and Clinical Research Institute, previously the Northern Institute for Cancer Research, and holds an honorary consultant position at Newcastle upon Tyne Hospitals NHS Foundation Trust. His research specializations encompass haematopathology, with a focus on the molecular genetics and pathology of lymphoid neoplasms, including paediatric lymphomas such as Burkitt lymphoma, anaplastic large cell lymphoma, and post-transplant lymphoproliferative disorders. Bacon investigates genetic abnormalities, prognostic markers, and immunotherapy responses in these malignancies, contributing to projects like the ITHACA study on immunological risk factors for post-transplant lymphoproliferative disease in children and the Lymphoma Research Group at Newcastle.

Bacon has an extensive publication record, with over 14,000 citations reflecting his influence in the field. Key works include co-authorship of 'The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms' (Leukemia, 2022), 'Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study' (Journal of Allergy and Clinical Immunology, 2017), and 'IRF8 Mutations and Human Dendritic-Cell Immunodeficiency' (New England Journal of Medicine, 2011). Earlier contributions advanced understanding of cytokine signaling, such as 'Interaction of IL-2Rβ and γc Chains with Jak1 and Jak3: Implications for XSCID and XCID' (Science, 1994) and 'Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes' (Proceedings of the National Academy of Sciences, 1995). Recent studies explore monocarboxylate transporter inhibition in diffuse large B-cell lymphoma and Burkitt lymphoma (Haematologica, 2017), and spatial profiling in classic Hodgkin lymphoma. His collaborations span international efforts in lymphoma classification, genomic profiling, and precision medicine through initiatives like DeepCPath.